Alto Neuroscience (ANRO)

• Market cap: $412M
• 1 day: -4.26%
• 5 days: 2.4%
• 1 month: 4%
• 3 months: 251.46%
• 6 months: 421.65%
• Year to date: 202.51%
• 1 year: 258.11%
• 5 years: -35.99%
• 10 years: -35.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76